Evidence map›Paper›PMID 41299753›Full record

ArticleEuropean journal of medical research2025

Single cell and machine learning identify type II pneumocyte-derived biomarkers HN1/OCIAD2/SFTA2 for non-small cell lung cancer prognosis and immune regulation.

Zhaofan Lin, Hanguang Yu, Kai Yang, Huijuan Xu

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhaofan LinDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Hanguang YuDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Kai YangDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Huijuan XuDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China. ilyhj121210@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) is one of the most prevalent malignancies and currently shows a poor clinical prognosis. Type II pneumocyte, as one of the main sources of cancer cells in NSCLC, is important to explore the molecular functions of its related markers for a deeper understanding of NSCLC.

methodsIn this study, NSCLC single-cell profiles and transcriptomic data were derived from Gene Expression Omnibus (GEO). Single-cell clustering was used to characterize the infiltration of type II pneumocyte and to reveal differences in the regulatory function of this cell compared to other cell subpopulations. Interactions between cellular subpopulations were clarified by CellChat. High-dimensional weighted gene co-expression network analysis (hdWGCNA) was utilized to mine modular signature genes closely relevant to type II pneumocyte in NSCLC. Differential expression analysis combined with least absolute shrinkage and selection operator (LASSO) and support vector machine recursive feature elimination (SVM-RFE), two machine learning algorithms, was used to screen key genes in NSCLC that are associated with disease progression and type II pneumocyte. The CIBERSORT and ESTIMATE algorithms were mainly used to assess the correlation between biomarkers and immune cell infiltration in NSCLC. Gene set enrichment analysis (GSEA) was used to evaluate the regulatory functions of biomarkers. CCK-8, Transwell assay, and wound healing assay were used to illustrate the regulation of biomarkers to NSCLC cell lines.

resultsSeven types of cell subpopulations were found in NSCLC samples, including macrophages, type II pneumocyte, T cell, ciliated cell, B cell, endothelial cell, and plasma cell. Among them, there is extensive cellular communication between type II pneumocyte and macrophages, mainly through ITGB2-ICAM1, HLA-DPB1-CD4, and HLA-DQB1-CD4 ligand-receptor pair binding. hdWGCNA combined with machine learning algorithms screened three key genes, HN1, OCIAD2, and SFTA2, associated with type II pneumocyte and NSCLC progression. Among them, HN1 and OCIAD2 were significantly negatively correlated with the stromal infiltration score, immunization score, and ESTIMATE score, respectively, whereas SFTA2 was significantly positively correlated with these three indicators. In vitro cellular assays indicate that HN1 and OCIAD2 are significantly upregulated in the NCI-H838 and A549 cell lines, whereas SFTA2 expression is downregulated. Furthermore, silencing HN1 significantly inhibits the proliferation, migration, and invasive capacity of NSCLC cell lines.

conclusionThis study elucidates genes in NSCLC that are highly associated with both disease progression and type II pneumocyte features as potential biomarkers of NSCLC, and predicts their potential regulatory functions as well as their impact on the immune infiltration profile of NSCLC, providing guidance for the unraveling of the immune mechanisms of NSCLC.

Indexed as

Alveolar Epithelial CellsBiomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsMachine LearningGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisSingle-Cell AnalysisTranscriptomeBiomarkers, TumorCell–cell contactHigh-dimension weighted gene co-expression network analysisImmunityMachine learningNon-small cell lung cancerType II pneumocyte

Identifiers

PMID41299753
PMCPMC12659147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.